The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy

Seminars in Surgical Oncology

Volumn 13, Issue 6, 1997, Pages 454-460

  Stock, Richard G ^a   Stone, Nelson N ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Interventional ultrasonography; Iodine radioisotopes; Neoplasm staging; Palladium; Patient selection; Prostate; Prostate specific antigen; Prostatic neoplasms; Radioisotopes

Indexed keywords

FLUTAMIDE; IODINE 125; PALLADIUM;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LOCALIZATION;

AGED; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030775175     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199711/12)13:6<454::AID-SSU10>3.0.CO;2-T     Document Type: Article

References (29)

1. Stock RG, Stone NN, DeWyngaert JK, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996;77:2386-2392.
2. 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096-1099.
3. Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453.
4. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. [comment in: J Urol 1993;150:1923-1924; J Urol 1994;152:172-173] J Urol 1993; 150:110-114.
5. Stock RG, Stone NN, Ianuzzi C, Unger P: Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:815-821.
6. Stone NN, Stock RG, Unger P: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995;154:1392-1396.
7. Stone NN, Stock RG, DeWyngaert JK, Tabert A: Prostate brachytherapy: improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry. Radiat Oncol Investig 1995;3: 185-195.
8. Stock RG, Stone NN, Wesson MF, DeWyngaert JK: A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995;32:219-225.
9. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep Part 1 1966;50:163-170.
11. Cox DR, Oakes D: Analysis of survival data. New York: Chapman and Hall, 1984.
12. Cox DR: Regression models and life tables. J R Stat Soc 1972;34:187-220.
13. Fienberg SE: "The analysis of cross-classified categorical data". 2nd ed. Cambridge, MA: MIT Press, 1980.
14. Zeitman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-645.
15. Zagars GK: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. [comment in: J Urol 1994;152 (5 Pt 2):1773-1774] J Urol 1994;152 (5 Pt 2):1786-1791.
16. Lee WR, Hanks GE, Schultheiss TE, et al: Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 1995; 13:464-469.
17. Beyer DC, Priestley JB Jr: Biochemical disease-free survival following I125 prostate implantation. Int J Radiat Oncol Biol Phys 1997;37:559-563.
18. Hanks GE, Lee WR, Schultheiss TE: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154 (2 Pt 1):456-459.
19. Zagars GK, Pollack A: Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-483.
20. Zeitman AL, Edelstein RA, Coen JJ, et al: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994;43:828-833.
21. Kupelian P, Katcher J, Levin H, et al: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249-260.
22. Roach M 3rd, Meehan S, Kroll S, et al: Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. [comment in: J Urol 1996;156:1724] J Urol 1996;156:1719-1723.
23. Kupelian P, Katcher J, Levin H, et al: External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pre-treatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997;3:78-87.
24. Stock RG, Stone NN, Iannuzzi C: Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996;35:267-272.
25. Zeitman AL, Nakfoor BM, Prince EA, Gerweck LE: The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997;3:31-36.
26. Laverdiere J, Gomez JL, Cusan L, et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. [comment in: Int J Radiat Oncol Biol Phys 1997;37:245-246] Int J Radiat Oncol Biol Phys 1997;37:247-252.
27. Dattoli M, Wallner K, Sorace R, et al: 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996;35: 875-879.
28. Blasko JC, Ragde H, Cavanagh W, et al: Long-term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer. [Abstract] Int J Radiat Oncol Biol Phys 1996;36(Suppl):198.
29. Critz FA, Levinson AK, Williams WH, Holloday DA: Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. [comment in. J Clin Oncol 1996;14:2889-2892] J Clin Oncol 1996;14:2893-2900.